| Avonex (recombinant IFN-β-1a) / Biogen |
NCT00292266: A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS) |
|
|
| Completed | 3 | 677 | US | Rebif®, Avonex® | EMD Serono, Merck Serono International SA | Multiple Sclerosis, Relapsing-Remitting | 06/02 | 06/02 | | |
NCT00030966: Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis |
|
|
| Completed | 3 | 1200 | US, Europe, RoW | Natalizumab, Tysabri, Placebo | Biogen, Elan Pharmaceuticals | Multiple Sclerosis, Relapsing-Remitting | 04/05 | 12/05 | | |
NCT00242268: A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis |
|
|
| Unknown status | 3 | 30 | US | Simvastatin | Alabama Neurology Associates, PC, Biogen | Relapsing Remitting Multiple Sclerosis | | | | |
NCT00915577: Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe |
|
|
| Completed | 3 | 74 | US | Interferon beta-1a, Avonex, Single-use autoinjector | Biogen | Multiple Sclerosis | 04/06 | 04/06 | | |
irmsrct, NCT00668343: Simvastatin in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Using Avonex Compared to Placebo |
|
|
| Completed | 3 | 80 | RoW | simvastatin, placebo | Tehran University of Medical Sciences | Relapsing Remitting Multiple Sclerosis | 03/08 | 03/09 | | |
NCT00784836 / 2008-003098-42: Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients |
|
|
| Terminated | 3 | 3 | US | BG9418 (interferon beta 1-a), Avonex | Biogen | Multiple Sclerosis | 02/09 | 02/09 | | |
NCT00828204: Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects |
|
|
| Completed | 3 | 95 | US | single-use autoinjector with a prefilled liquid Avonex syringe, Avonex prefilled syringe via manual IM injection, BG9418 (interferon beta-1a), Avonex | Biogen | Multiple Sclerosis | 07/10 | 10/10 | | |
|
BRAVO, NCT00605215 / 2007-005450-23: Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®) |
|
|
| Completed | 3 | 1331 | Europe, US, RoW | Laquinimod, Placebo, Avonex®, Interferon β-1a | Teva Branded Pharmaceutical Products R&D, Inc. | Multiple Sclerosis | 06/11 | 06/11 | | |
|
|
|
|
|
|
|
| Completed | 3 | 1292 | US, Canada, Europe, RoW | Fingolimod 1.25 mg, FTY720, Fingolimod 0.5 mg, Interferon β-1a 30 µg | Novartis | Multiple Sclerosis | 07/11 | 07/11 | | |
|
|
|
|
|
|
|
|
|
|
|
|
| Completed | 3 | 60 | RoW | Avonex | Biogen | Multiple Sclerosis | 10/11 | 10/11 | | |
NCT01064401 / 2009-012500-11: Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis |
|
|
| Completed | 3 | 1841 | US, Canada, Europe, RoW | BIIB019 (Daclizumab High Yield Process), DAC HYP, Interferon beta-1a Placebo, Interferon beta-1a, Avonex, IFN β-1a, Daclizumab High Yield Process Placebo | Biogen, AbbVie | Relapsing-Remitting Multiple Sclerosis | 03/14 | 07/14 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIBRETTO, NCT01975298 / 2013-002082-19: A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) |
|
|
| Withdrawn | 3 | 0 | NA | Laquinimod, TV-5600, Avonex®, Interferon β1A | Teva Branded Pharmaceutical Products R&D, Inc. | Relapsing Remitting Multiple Sclerosis | 03/14 | 03/14 | | |
2013-003126-83: Study which compares the effectiveness and safety of a not yet approved drug called ONO-4641 versus an approved drug called interferon beta 1a (active comparator) in patients with multiple sclerosis. The study is double-blind (that is when neither the patient nor the investigator know which of the 2 drugs the patient is receiving). Patients will be randomly assigned (like the flip of a coin) to receive the study drug (two different doses) or the comparator. |
|
|
| Completed | 3 | 1176 | Europe, RoW | Avonex, MSC2430913A or ONO-4641 (to be used as synonyms), Film-coated tablet, Solution for infusion in pre-filled syringe, Avonex | Merck KGaA, Merck KGaA | Relapsing multiple sclerosis, Multiple sclerosis, Diseases [C] - Nervous System Diseases [C10] | | | | |
2006-004937-13: multicentee randomized controlled study of azathioprine versus iterferon beta in relapsing remitting multiple sclerosis |
|
|
| Ongoing | 3 | 360 | Europe | AZATIOPRINA HEX. 50CPR 50MG BL, REBIF SC 12SIR 6000000UI 22MCG, BETAFERON SC 15F 0,25MG 15SIR, REBIF SC 12SIR 12000000UI44MCG, AVONEX IM 4SIR 30MCG/0,5ML 4AG, AZATIOPRINA HEX. 50CPR 50MG BL, REBIF SC 12SIR 6000000UI 22MCG, BETAFERON SC 15F 0,25MG 15SIR, REBIF SC 12SIR 12000000UI44MCG, AVONEX IM 4SIR 30MCG/0,5ML 4AG | Universita di Firenze | patients with relapsing remitting multiple sclerosis | | | | |
2006-000704-17: A 12-month double-blind, randomized, multicenter, active controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily versus interferon β-1a (Avonex®) administered i.m. once weekly in patients with relapsing-remitting multiple sclerosis with optional Extension Phase |
|
|
| | 3 | 220 | Europe | Interferon beta-1a, FTY720, AVONEX, AVONEX | Novartis Pharma Services AG, Novartis Farmacéutica, S.A., NOVARTIS FARMA | Relapsing-remitting multiple sclerosis (RRMS) | | 07/11 | | |
2008-007162-32: ADVANCED MRI STUDY ON INFLAMMATORY AND DEGENRATIVE DAMAGE IN MULTIPLE SCLEROSIS |
|
|
| Ongoing | 3 | 50 | Europe | COPAXONE, AVONEX, COPAXONE, AVONEX | ISTITUTO C. MONDINO | Multiple Sclerosis | | | | |
2013-002351-15: Study which compares the effectiveness and safety of a not yet approved drug called ONO-4641 versus an approved drug called interferon beta 1a (active comparator) in patients with multiple sclerosis. The study is double-blind (that is when neither the patient nor the investigator know which of the 2 drugs the patient is receiving). Patients will be randomly assigned (like the flip of a coin) to receive the study drug (two different doses) or the comparator. |
|
|
| | 3 | 88 | Europe | Avonex, MSC2430913A or ONO-4641 (to be used as synonyms), Avonex, Avonex | Merck KGaA, Merck KGaA | Relapsing remitting multiple sclerosis | | 08/14 | | |
| Completed | 3 | 1346 | Europe, Canada, US, RoW | Ozanimod, RPC1063, Zeposia®, Interferon beta-1a, Avonex®, IFN β-1a, Placebo to ozanimod, Placebo to interferon beta-1a | Celgene | Multiple Sclerosis | 12/16 | 12/16 | | |
| Completed | 3 | 1320 | Europe, Canada, US, RoW | Ozanimod, RPC1063, Zeposia®, Ozanimod placebo, Interferon beta-1a, Avonex, Interferon beta-1a placebo | Celgene, Receptos, Inc., Celgene International II Sàrl (CIS II) | Relapsing Multiple Sclerosis | 03/17 | 04/17 | | |
2018-001292-21: Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years Arrêt des traitements de fond à visée immunologique chez les patients de plus de 50 ans ayant une sclérose en plaques secondairement progressive |
|
|
| Not yet recruiting | 3 | 250 | Europe | AVONEX, BETAFERON, EXTAVIA, REBIF, PLEDIGRY, COPAXONE, AUBAGIO, TECFIDERA, GILENYA, TYSABRI, IMUREL, NOVATREX, CELLCEPT, ENDOXAN, L03 AB 08, Concentrate for solution for injection, Powder for solution for injection, Solution for injection, Solution for injection in pre-filled syringe, Tablet, Capsule, Concentrate for solution for infusion | CHU de Rennes, CHU de Rennes | Secondary Progressive Multiple Sclerosis Sclérose en plaques secondairement progressive, Secondary Progressive Multiple Sclerosis Sclérose en plaques secondairement progressive, Diseases [C] - Nervous System Diseases [C10] | | | | |
| Terminated | 3 | 3 | Europe, US | Evobrutinib, M2951, Avonex®, Avonex® matched Placebo, Evobrutinib matched Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Relapsing-remitting Multiple Sclerosis | 04/20 | 04/20 | | |
| Terminated | 3 | 1 | Europe, US | Evobrutinib, M2951, Avonex®, Avonex® matched Placebo, Evobrutinib matched Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Relapsing-remitting Multiple Sclerosis | 05/20 | 05/20 | | |
| Active, not recruiting | 3 | 156 | Europe, Canada, US, RoW | dimethyl fumarate, BG00012, Tecfidera, Interferon β-1a, Avonex | Biogen | Relapsing-Remitting Multiple Sclerosis | 09/25 | 09/25 | | |
NCT03958877 / 2018-003008-38: A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis |
|
|
| Recruiting | 3 | 142 | Europe, US, RoW | BIIB017 (peginterferon beta-1a), PLEGRIDY, Interferon beta type 1a, Avonex | Biogen | Multiple Sclerosis, Relapsing-Remitting | 07/24 | 05/27 | | |
NCT00223301: Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis |
|
|
| Completed | 2/3 | 24 | US | Mycophenolate Mofetil (cellcept) | University of Texas Southwestern Medical Center, Roche Pharma AG, Biogen | Multiple Sclerosis | 03/07 | 03/07 | | |
NCT02744222: Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis |
|
|
| Completed | 2/3 | 399 | RoW | BCD-054 180 mcg, pegylated interferon beta-1a, Avonex®, interferon beta-1a, BCD-054 240 mcg, Placebo | Biocad | Multiple Sclerosis, Relapsing-Remitting | 11/18 | 07/20 | | |
| Recruiting | 2/3 | 5 | Europe | Tecfidera (BG12), Gilenya, fingolimod, Tysabri®, natalizumab, Avonex/Betaseron/Copaxone/Rebif, (Avonex®, Betaseron®, Copaxone®, Rebif®), Hematopoietic stem cell transplantation (HSCT) | Sheffield Teaching Hospitals NHS Foundation Trust | Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | 12/21 | 12/21 | | |
